



SPANDIDOS
PUBLICATIONS



WORLD
ACADEMY
OF SCIENCES



30 March - 1 April 2023
Park Plaza Hotel
Santiago, Chile

25th International Symposium on Molecular Medicine



UNIVERSIDAD
DE CHILE

Program

GENERAL INFORMATION

SYMPOSIUM VENUE

Park Plaza Hotel, Santiago, Chile

REGISTRATION DESK:

Thursday	30 March	08.00 - 13.00 and 15.00 - 17.00 hrs
Friday	31 March	08.00 - 13.00
Saturday	1 April	08.00 - 13.00

REGISTRATION FEE

Active participant	USD 200
Accompanying person	USD 100

The registration fee includes:

- Coffee/Tea

Optional

- Buffet Lunch (USD 29)
- Buffet Dinner (USD 29)

Scientific Program

BIOCHEMISTRY/MOLECULAR ONCOLOGY

09:00-11:00

Thursday, March 30

Chair Persons: G.M. Calaf, P. Bouvet, C. Romero

- 111. Interplay between organophosphorous pesticides, acetylcholine, and estrogen receptor in breast carcinogenesis. **G. Calaf** (Chile) (30')
- 106. Functions of a major nucleolar protein, nucleolin, in oncogenesis. **P. Bouvet** (France) (30')
- 114. MicroRNAs as new complementary therapy for ovarian cancer. **C. Romero** (Chile) (20')
- 113. Development of DeepSnap, a novel *in silico* technology for predicting toxicity from chemical structures. **Y. Uesawa** (Japan) (20')
- 109. Use of drug repositioning for chemosensitization of epithelial ovarian cancer cells. **M. Garrido** (Chile) (20')

COFFEE/TEA BREAK

11:00-11:30

MOLECULAR ONCOLOGY/PHARMACOLOGY

11:30-13:00

Thursday, March 30

Chair Persons: J.S. Huang, A. Vilorio-Petit, D.E. Gomez

- 103. Hallmarks of cancer: loss of TGF- β type V receptor (T β R-V) expression changing TGF- β from a tumor suppressor to a tumor promoter. **J.S. Huang** (USA) (25')
- 120. Comparative oncology as a feasible strategy for molecular target discovery in osteosarcoma. **A. Vilorio-Petit** (Canada) (25')
- 140. PIN1 as a molecular target for glioblastoma treatment: target validation, inhibitors rational design and biological activity determination. **D.E. Gomez** (Argentina) (25')
- 115. Molecular and clinical features of aggressive thyroid cancer. **A. Antonelli** (Italy) (8')
- 130. The efficacy of Pazopanib in the treatment of anaplastic thyroid cancer in primary culture. **P. Fallahi** (Italy) (7')

Chair Persons: Y. Ni, T. Vasilenko, P. Gal

- 104. An emerging technique for dual-targeting chemo-radio-ablation of generic micro-cancers in conjunction with cancer liquid biopsy. **Y. Ni** (Belgium) (20')
- 116. Agrimonia eupatoria L.: effective modulator of skin wound healing. **T. Vasilenko** (Slovakia) (20')
- 117. Novel approaches to treat (infected) wounds. **P. Gal** (Slovakia) (20')
- 127. Thyroid carcinoma: Germline DNA variant markers and cardiometabolic risk diseases. **T. Matakova** (Slovakia) (20')
- 128. Achievements in prevention, early detection and treatment of lung cancer. **E. Halasova** (Slovakia) (20')
- 122. Screening of mitochondrial DNA mutations among hypertension patients from District Skardu. **M. Hasnain** (Pakistan) (10')
- 139. Water, sanitation and hygiene. **D. Forjindam** (Cameroon) (10')

MOLECULAR MEDICINE/CLINICAL ONCOLOGY

09:00-11:00
Friday, March 31

Chair Persons: R.J. Reiter, R. Carrasco, A. El-Naggar

- 101. Melatonin: Its expanding universe. **R.J. Reiter** (USA) (30')
- 121. Targeting the Wnt/ β -catenin/BCL9 transcriptional complex for cancer therapy. **R. Carrasco** (USA) (30')
- 118. Targeted therapy of orphan head and neck cancers. **A. El-Naggar** (USA) (30')
- 123. An uncommon genetic landscape and clinical spectrum in Italian patients referred for recurrent fever. **A. Stella** (Italy) (30')

COFFEE/TEA BREAK

11:00-11:30

IMMUNOTHERAPY/MOLECULAR MEDICINE

11:30-13:00
Friday, March 31

Chair Persons: M. Vega Blanco, L. Cuitino, W. Zhu

- 110. Impact of the hormone microenvironment on human endometrial function. **M. Vega Blanco** (Chile) (20')
- 124. Evaluation of potential biomarkers of disease activity in non- infectious uveitis. **L. Cuitino** (Chile) (20')
- 138. TDO2-Kynurine pathway in CRPC. **R.K. Sah** (China) (10')
- 107. Gold nanoparticles from *Peganum harmala*, *Artimesia absinthium* and *Morus nigra*: biosynthesis, characterization and cytotoxic activity against cancer cell lines. **H. Sadeghi-Aliabadi** (Iran) (10')
- 131. Naproxen activation of novel death pathway in colorectal cancer cell. **W. Zhu** (USA) (10')
- 132. Artemisinin and artesunate mitigate colon cancer cell migration and apoptosis. **W. Zhu** (USA) (10')
- 133. Cytotoxic effect of potassium bromate on human cells. **W. Zhu** (USA) (10')

MOLECULAR/CLINICAL ONCOLOGY

09:00-11:00

Saturday, April 1

Chair Persons: D. Tan, O. Tsitsilonis, P. Szabo

- 119. Molecular tests in guiding personalized medicine of solid malignancies. **D. Tan** (USA) (25')
- 112. The significance of MRD detection in multiple myeloma. **O. Tsitsilonis** (Greece) (25')
- 129. Cancer microenvironment in pancreatic ductal adenocarcinoma. **P. Szabo** (Czech Republic) (25')
- 108. Implication of genetic variants in the therapeutic intervention of hydroxy urea among thalassaemia major patients. **I. Qadeer** (Pakistan) (15')
- 134. Metformin exhibits novel anti-amyloid beta peptide activity on human immune cells. **W. Zhu** (USA) (10')
- 135. Neuroprotective effects of naringenin against Parkinson's disease. **W. Zhu** (USA) (10')
- 136. E-cigarette constituent propylene glycol's induce human alveolar and aeuronal cell apoptosis via TNFR2 signaling pathway. **W. Zhu** (USA) (10')

COFFEE/TEA BREAK

11:00-11:30

MOLECULAR PATHOGENESIS/TOXICOLOGY/ONCOLOGY

11:30-13:00

Saturday, April 1

Chair Persons: L. Chirieac, V.E. Georgakopoulou, D. Kouretas

- 137. Novel insights and recent discoveries on the genetics and pathogenesis of malignant mesothelioma. **L. Chirieac** (30')
- 125. Immature granulocytes: Innovative biomarker for SARS CoV 2 infection. **V.E. Georgakopoulou** (Greece) (15')
- 126. Lung function at 3 months after hospitalization due to COVID-19 pneumonia: comparison of alpha, delta, and omicron variant predominance. **V.E. Georgakopoulou** (Greece) (15')
- 105. Reconceptualization of hormetic responses in the frame of redox toxicology. **D. Kouretas** (Greece) (10')
- 102. Publishing in biomedical sciences. **D.A. Spandidos** (Greece) (20')